BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22495787)

  • 21. A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom formulations in women from Cameroon.
    Mbopi-Keou FX; Trottier S; Omar RF; Nkele NN; Fokoua S; Mbu ER; Giguere JF; Domingo MC; Piret J; Tsague L; Zekeng L; Mwatha A; Mâsse B; Bergeron MG
    Contraception; 2009 Nov; 80(5):484-92. PubMed ID: 19835725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa.
    van de Wijgert JH; Braunstein SL; Morar NS; Jones HE; Madurai L; Strickfaden TT; Moodley M; Aboobaker J; Ndlovu G; Ferguson TM; Friedland BA; Hart CE; Ramjee G
    J Acquir Immune Defic Syndr; 2007 Dec; 46(5):538-46. PubMed ID: 18193495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women.
    Mbopi-Keou FX; Trottier S; Omar RF; Nkele NN; Fokoua S; Mbu ER; Domingo MC; Giguère JF; Piret J; Mwatha A; Mâsse B; Bergeron MG
    Contraception; 2010 Jan; 81(1):79-85. PubMed ID: 20004278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1.
    Hossain MM; Parniak MA
    J Virol; 2006 May; 80(9):4440-6. PubMed ID: 16611904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
    Nel AM; Coplan P; van de Wijgert JH; Kapiga SH; von Mollendorf C; Geubbels E; Vyankandondera J; Rees HV; Masenga G; Kiwelu I; Moyes J; Smythe SC
    AIDS; 2009 Jul; 23(12):1531-8. PubMed ID: 19550287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use: Findings from the Carraguard Phase 3 Trial.
    Friedland BA; Stoner M; Chau MM; Plagianos MG; Govender S; Morar N; Altini L; Skoler-Karpoff S; Ahmed K; Ramjee G; Monedi C; Maguire R; Lähteenmäki P
    AIDS Behav; 2016 Nov; 20(11):2565-2577. PubMed ID: 26204987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and characterisation of a self-microemulsifying drug delivery systems (SMEDDSs) for the vaginal administration of the antiretroviral UC-781.
    McConville C; Friend D
    Eur J Pharm Biopharm; 2013 Apr; 83(3):322-9. PubMed ID: 23159711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel.
    Teleshova N; Keller MJ; Fernández Romero JA; Friedland BA; Creasy GW; Plagianos MG; Ray L; Barnable P; Kizima L; Rodriguez A; Cornejal N; Melo C; Cruz Rodriguez G; Mukhopadhyay S; Calenda G; Sinkar SU; Bonnaire T; Wesenberg A; Zhang S; Kleinbeck K; Palmer K; Alami M; O'Keefe BR; Gillevet P; Hur H; Liang Y; Santone G; Fichorova RN; Kalir T; Zydowsky TM
    PLoS One; 2022; 17(1):e0261775. PubMed ID: 35051209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rectal microbicide development.
    McGowan I
    Curr Opin HIV AIDS; 2012 Nov; 7(6):526-33. PubMed ID: 23032732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.
    Bunge KE; Dezzutti CS; Rohan LC; Hendrix CW; Marzinke MA; Richardson-Harman N; Moncla BJ; Devlin B; Meyn LA; Spiegel HM; Hillier SL
    J Acquir Immune Defic Syndr; 2016 Apr; 71(5):498-505. PubMed ID: 26565716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers.
    Jespers VA; Van Roey JM; Beets GI; Buvé AM
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):154-8. PubMed ID: 17106275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781.
    Clark MR; Johnson TJ; McCabe RT; Clark JT; Tuitupou A; Elgendy H; Friend DR; Kiser PF
    J Pharm Sci; 2012 Feb; 101(2):576-87. PubMed ID: 21976110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women.
    Mayer KH; Karim SA; Kelly C; Maslankowski L; Rees H; Profy AT; Day J; Welch J; Rosenberg Z;
    AIDS; 2003 Feb; 17(3):321-9. PubMed ID: 12556685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acceptability and adherence: findings from a Phase II study of a candidate vaginal microbicide, 'Praneem polyherbal tablet', in Pune, India.
    Joglekar NS; Joshi SN; Deshpande SS; Parkhe AN; Katti UR; Mehendale SM
    Trans R Soc Trop Med Hyg; 2010 Jun; 104(6):412-5. PubMed ID: 20096909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acceptability of Praneem polyherbal vaginal tablet among HIV uninfected women & their male partners in Pune, India--Phase I study.
    Joglekar NS; Joshi SN; Navlakha SN; Katti UR; Mehendale SM
    Indian J Med Res; 2006 Apr; 123(4):547-52. PubMed ID: 16783046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.
    Rosen RK; Morrow KM; Carballo-Diéguez A; Mantell JE; Hoffman S; Gai F; Maslankowski L; El-Sadr WM; Mayer KH
    J Womens Health (Larchmt); 2008 Apr; 17(3):383-92. PubMed ID: 18328009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, comparative safety study of a prefilled plastic and user-filled paper applicator with candidate microbicide tenofovir 1% gel.
    Cohen JA; Brache V; Foster J; Cochon L; Callahan M; Schwartz J
    Sex Transm Dis; 2013 Jun; 40(6):476-81. PubMed ID: 23677021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the potential of the Woman's Condom for vaginal drug delivery.
    Kramzer LF; Cohen J; Schubert J; Dezzutti CS; Moncla BJ; Friend D; Rohan LC
    Contraception; 2015 Sep; 92(3):254-60. PubMed ID: 25998936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Pilot Study Measuring the Distribution and Permeability of a Vaginal HIV Microbicide Gel Vehicle Using Magnetic Resonance Imaging, Single Photon Emission Computed Tomography/Computed Tomography, and a Radiolabeled Small Molecule.
    Fuchs EJ; Schwartz JL; Friend DR; Coleman JS; Hendrix CW
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1109-15. PubMed ID: 26077739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand.
    Kilmarx PH; Blanchard K; Chaikummao S; Friedland BA; Srivirojana N; Connolly C; Witwatwongwana P; Supawitkul S; Mock PA; Chaowanachan T; Tappero J
    Sex Transm Dis; 2008 Mar; 35(3):226-32. PubMed ID: 18490865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.